2024-01-092024-01-092016Deligönül, A. vd. (2016). "Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer". Journal of BUON, 21(3), 564-569.1107-06252241-6293https://europepmc.org/article/med/27569073https://hdl.handle.net/11452/38882Purpose: The clinical value of HER4 - a cell surface receptor that belongs to the human epidermal growth factor receptor family - for predicting survival outcomes in patients with breast cancer remains controversial. Herein, we sought to investigate the prognostic significance of HER4 immunohistochemical expression with respect to progression-free survival (PFS) and overall survival (OS) in Turkish patients with metastatic breast cancer (MBC).Methods: MBC patients (N=45; mean age=50.5 +/- 12.7 years) were consecutively enrolled between 2000 and 2006 in the Department of Oncology at the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. The predictive value of HER4 expression was investigated by multivariate analysis after allowance for potential confounders.Results: The mean PFS in the study participants was 11.35 months (range:1-50), whereas the median OS was 22.18 months (range:1-76). The mean PFS in patients with a HER4 immunohistochemical score of 0, 1+, 2+, and 3+ was 11.0 +/- 4.8, 11.3 +/- 7.7, 11.7 +/- 8.1, and 10.4 +/- 7.4 months, respectively (p=0.99). The mean OS in patients with a HER4 score of 0, 1+, 2+, and 3+ was 13.3 +/- 6.8, 25.6 +/- 10.8, 22.9 +/- 10.7, and 13.5 +/- 9.9, months, respectively (p=0.44). The results of multivariate Cox regression analysis indicated that the presence of visceral metastases was the only independent prognostic factor for both OS (HR=3.01, 95% CI=1.56-3.99, p <0.01) and PFS (HR=2.91, 95% CI=1.51-3.78, p <0.01).Conclusion: HER4 immunohistochemical expression is not an independent predictor of OS and PFS in Turkish MBC patients.eninfo:eu-repo/semantics/closedAccessOncologyHER4ImmunochemistryMetastatic breast cancerPrognosisSurvivalProgesterone-receptorEstrogen-receptorSystemic therapyBh3-only proteinCoactivatorERBB4/HER4CarcinomasRecurrenceHER4/4ICDFamilyAdultAgedBreast neoplasmsFemaleHumansImmunohistochemistryMiddle agedNeoplasm metastasisPrognosisProportional hazards modelsReceptor, ErbB-4Article0003789789000052-s2.0-8499416440456456921327569073OncologyErbb-3 Receptor; U3-1287; CancerAnthracyclineEpidermal growth factor receptor 2Epidermal growth factor receptor 4Estrogen receptorProgesterone receptorTaxane derivativeEpidermal growth factor receptor 4AdultArticleCancer gradingCancer localizationCancer prognosisClinical articleFemaleFollow upHumanImmunohistochemistryMetastatic breast cancerMiddle agedOverall survivalProgression free survivalProtein expressionRetrospective studyTumor growthTumor volumeTurk (people)AgedBreast tumorChemistryImmunohistochemistryMetastasisMortalityPathologyPrognosisProportional hazards model